NRx Pharmaceuticals, Inc. (NRXP)

NRx Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	28	39	75	281	66	64
Market Cap Growth	-4.25%	-48.59%	-73.29%	328.57%	1.96%	-30.20%
Enterprise Value	33	43	66	254	65	67
PE Ratio	-	-1.28	-1.89	-0.81	-1.27	-9.56
PB Ratio	-3.00	-3.29	10.13	13.51	-1.50	-13.26
P/FCF Ratio	-2.35	-1.78	-1.89	-7.45	-28.93	-11.60
P/OCF Ratio	-2.35	-1.78	-1.89	-7.46	-28.96	-11.61
EV/EBITDA Ratio	-2.00	-1.44	-1.65	-2.73	-1.25	-10.46
EV/EBIT Ratio	-2.00	-1.44	-1.65	-2.73	-1.25	-10.46
EV/FCF Ratio	-2.63	-1.99	-1.65	-6.74	-28.47	-12.12
Debt / Equity Ratio	-0.45	-0.78	1.42	0.02	-0.02	-0.77
Debt / EBITDA Ratio	-0.27	-0.31	-0.26	-0.01	-0.02	-0.58
Debt / FCF Ratio	-0.35	-0.42	-0.26	-0.01	-0.35	-0.68
Quick Ratio	0.07	0.24	1.29	2.32	0.06	0.37
Current Ratio	0.18	0.36	1.66	2.74	0.06	0.41
Interest Coverage	-72.25	-250.25	-	-5169.17	-923.59	-21.20
Return on Equity (ROE)	286.40%	573.30%	-195.80%	34059.90%	624.40%	-265.20%
Return on Assets (ROA)	-233.00%	-194.50%	-125.50%	-1267.50%	-965.90%	-16.40%
Return on Capital (ROIC)	294.33%	1082.31%	-247.21%	-543.03%	119.58%	566.96%
Earnings Yield	-92.19%	-78.13%	-52.95%	-124.11%	-78.94%	-10.46%
FCF Yield	-69.15%	-56.11%	-52.96%	-13.41%	-3.46%	-8.62%
Buyback Yield / Dilution	-33.17%	-15.20%	-40.17%	-36.90%	-220.58%	-308.88%
Total Shareholder Return	-33.17%	-15.20%	-40.17%	-36.90%	-220.58%	-308.88%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).